Skip to main content
NASDAQ:BMEA

Biomea Fusion Competitors

$15.91
+0.03 (+0.19 %)
(As of 05/13/2021 12:00 AM ET)
Add
Compare
Today's Range
$14.11
$16.94
50-Day Range N/A
52-Week Range
$14.10
$22.22
Volume171,810 shs
Average Volume125,474 shs
Market Capitalization$457.70 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Biomea Fusion (NASDAQ:BMEA) Vs. IMCR, SEER, IBRX, BCAB, CGEM, and EWTX

Should you be buying BMEA stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Biomea Fusion, including Immunocore (IMCR), Seer (SEER), ImmunityBio (IBRX), BioAtla (BCAB), Cullinan Oncology (CGEM), and Edgewise Therapeutics (EWTX).

Immunocore (NASDAQ:IMCR) and Biomea Fusion (NASDAQ:BMEA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, risk, profitability, analyst recommendations and dividends.

Profitability

This table compares Immunocore and Biomea Fusion's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunocoreN/AN/AN/A
Biomea FusionN/AN/AN/A

Earnings & Valuation

This table compares Immunocore and Biomea Fusion's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunocoreN/AN/AN/AN/AN/A
Biomea FusionN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of current recommendations and price targets for Immunocore and Biomea Fusion, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Immunocore01202.67
Biomea Fusion00303.00

Immunocore currently has a consensus target price of $54.3333, suggesting a potential upside of 33.33%. Biomea Fusion has a consensus target price of $26.3333, suggesting a potential upside of 65.51%. Given Biomea Fusion's stronger consensus rating and higher probable upside, analysts clearly believe Biomea Fusion is more favorable than Immunocore.

Summary

Biomea Fusion beats Immunocore on 3 of the 3 factors compared between the two stocks.

Seer (NASDAQ:SEER) and Biomea Fusion (NASDAQ:BMEA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

Profitability

This table compares Seer and Biomea Fusion's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SeerN/AN/AN/A
Biomea FusionN/AN/AN/A

Valuation and Earnings

This table compares Seer and Biomea Fusion's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SeerN/AN/AN/AN/AN/A
Biomea FusionN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Seer and Biomea Fusion, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Seer02202.50
Biomea Fusion00303.00

Seer presently has a consensus target price of $66.3333, suggesting a potential upside of 130.40%. Biomea Fusion has a consensus target price of $26.3333, suggesting a potential upside of 65.51%. Given Seer's higher probable upside, research analysts clearly believe Seer is more favorable than Biomea Fusion.

Summary

Biomea Fusion beats Seer on 2 of the 3 factors compared between the two stocks.

ImmunityBio (NASDAQ:IBRX) and Biomea Fusion (NASDAQ:BMEA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

Profitability

This table compares ImmunityBio and Biomea Fusion's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunityBioN/AN/AN/A
Biomea FusionN/AN/AN/A

Valuation and Earnings

This table compares ImmunityBio and Biomea Fusion's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunityBioN/AN/AN/AN/AN/A
Biomea FusionN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings and target prices for ImmunityBio and Biomea Fusion, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ImmunityBio00103.00
Biomea Fusion00303.00

ImmunityBio presently has a consensus target price of $25.00, suggesting a potential upside of 72.89%. Biomea Fusion has a consensus target price of $26.3333, suggesting a potential upside of 65.51%. Given ImmunityBio's higher probable upside, research analysts clearly believe ImmunityBio is more favorable than Biomea Fusion.

BioAtla (NASDAQ:BCAB) and Biomea Fusion (NASDAQ:BMEA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

Profitability

This table compares BioAtla and Biomea Fusion's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioAtlaN/AN/AN/A
Biomea FusionN/AN/AN/A

Valuation and Earnings

This table compares BioAtla and Biomea Fusion's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioAtlaN/AN/AN/AN/AN/A
Biomea FusionN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings and target prices for BioAtla and Biomea Fusion, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioAtla00403.00
Biomea Fusion00303.00

BioAtla presently has a consensus target price of $62.75, suggesting a potential upside of 37.67%. Biomea Fusion has a consensus target price of $26.3333, suggesting a potential upside of 65.51%. Given Biomea Fusion's higher probable upside, analysts clearly believe Biomea Fusion is more favorable than BioAtla.

Cullinan Oncology (NASDAQ:CGEM) and Biomea Fusion (NASDAQ:BMEA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Cullinan Oncology and Biomea Fusion, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cullinan Oncology00403.00
Biomea Fusion00303.00

Cullinan Oncology presently has a consensus target price of $48.75, suggesting a potential upside of 75.68%. Biomea Fusion has a consensus target price of $26.3333, suggesting a potential upside of 65.51%. Given Cullinan Oncology's higher probable upside, research analysts clearly believe Cullinan Oncology is more favorable than Biomea Fusion.

Profitability

This table compares Cullinan Oncology and Biomea Fusion's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cullinan OncologyN/AN/AN/A
Biomea FusionN/AN/AN/A

Valuation and Earnings

This table compares Cullinan Oncology and Biomea Fusion's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cullinan OncologyN/AN/AN/AN/AN/A
Biomea FusionN/AN/AN/AN/AN/A

Summary

Cullinan Oncology beats Biomea Fusion on 2 of the 2 factors compared between the two stocks.

Biomea Fusion (NASDAQ:BMEA) and Edgewise Therapeutics (NASDAQ:EWTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, institutional ownership and dividends.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Biomea Fusion and Edgewise Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Biomea Fusion00303.00
Edgewise Therapeutics01302.75

Biomea Fusion presently has a consensus price target of $26.3333, indicating a potential upside of 65.51%. Edgewise Therapeutics has a consensus price target of $34.25, indicating a potential upside of 35.97%. Given Biomea Fusion's stronger consensus rating and higher probable upside, equities analysts plainly believe Biomea Fusion is more favorable than Edgewise Therapeutics.

Profitability

This table compares Biomea Fusion and Edgewise Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Biomea FusionN/AN/AN/A
Edgewise TherapeuticsN/AN/AN/A

Earnings & Valuation

This table compares Biomea Fusion and Edgewise Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biomea FusionN/AN/AN/AN/AN/A
Edgewise TherapeuticsN/AN/AN/AN/AN/A

Summary

Biomea Fusion beats Edgewise Therapeutics on 2 of the 2 factors compared between the two stocks.


Biomea Fusion Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Immunocore logo
IMCR
Immunocore
1.3$40.75+0.4%$1.76 billionN/A0.00
SEER
Seer
1.1$28.79+0.1%$1.75 billionN/A0.00Earnings Announcement
Analyst Report
IBRX
ImmunityBio
1.7$14.46+5.0%$1.58 billionN/A0.00Upcoming Earnings
News Coverage
Gap Up
BioAtla logo
BCAB
BioAtla
1.7$45.58+5.3%$1.53 billionN/A0.00Earnings Announcement
News Coverage
Cullinan Oncology logo
CGEM
Cullinan Oncology
1.4$27.75+9.7%$1.21 billionN/A0.00
EWTX
Edgewise Therapeutics
1.8$25.19+4.5%$1.20 billionN/A0.00
Nurix Therapeutics logo
NRIX
Nurix Therapeutics
2.0$25.20+3.3%$1.12 billionN/A0.00
KNTE
Kinnate Biopharma
1.7$22.19+6.0%$964.98 millionN/A0.00
CNTB
Connect Biopharma
1.7$15.50+0.6%$891.31 millionN/A0.00
Silverback Therapeutics logo
SBTX
Silverback Therapeutics
1.7$24.71+7.1%$862.45 millionN/A0.00News Coverage
STEM
Stem
0.0$16.38+11.1%$785.39 millionN/A0.00
iTeos Therapeutics logo
ITOS
iTeos Therapeutics
1.9$22.36+0.9%$784.86 millionN/A0.00Earnings Announcement
Analyst Report
Pharming Group logo
PHAR
Pharming Group
0.0$11.91+9.2%$763.78 millionN/A0.00News Coverage
Gap Down
Vor Biopharma logo
VOR
Vor Biopharma
1.5$19.70+8.1%$731.50 millionN/A0.00Analyst Upgrade
Gap Up
Pharvaris B.V. logo
PHVS
Pharvaris B.V.
1.5$22.25+0.1%$708.44 millionN/A0.00
FDMT
4D Molecular Therapeutics
1.3$26.42+4.4%$705.26 millionN/A0.00News Coverage
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.3$18.33+4.7%$665.89 millionN/A0.00
Gracell Biotechnologies logo
GRCL
Gracell Biotechnologies
1.4$9.75+12.5%$655.33 millionN/A0.00
FNCH
Finch Therapeutics Group
2.0$12.03+2.0%$567.15 millionN/A0.00
Inventiva logo
IVA
Inventiva
1.4$14.15+1.1%$546.61 millionN/A0.00
VACC
Vaccitech
0.3$15.75+8.6%$536.51 millionN/A0.00Gap Up
ACHL
Achilles Therapeutics
1.6$12.61+3.2%$512.24 millionN/A0.00Earnings Announcement
Quiet Period Expiration
Gap Up
MIGI
Mawson Infrastructure Group
0.0$0.89+6.7%$471.73 millionN/A0.00Upcoming Earnings
VECT
VectivBio
1.6$12.69+2.2%$431.65 millionN/A0.00Quiet Period Expiration
SGTX
Sigilon Therapeutics
1.4$13.25+6.0%$417.77 millionN/A0.00Earnings Announcement
Analyst Revision
News Coverage
Angion Biomedica logo
ANGN
Angion Biomedica
1.6$14.00+3.9%$412.78 millionN/A0.00
Landos Biopharma logo
LABP
Landos Biopharma
1.5$10.20+0.9%$409.20 millionN/A0.00
RAIN
Rain Therapeutics
1.3$15.08+5.5%$391.61 millionN/A0.00
NexImmune logo
NEXI
NexImmune
2.0$17.15+7.7%$390.30 millionN/A0.00
Terns Pharmaceuticals logo
TERN
Terns Pharmaceuticals
1.7$15.16+1.3%$380.90 millionN/A0.00
Gemini Therapeutics logo
GMTX
Gemini Therapeutics
1.7$8.62+0.3%$370.65 millionN/A0.00News Coverage
PRTG
Portage Biotech
0.0$28.04+1.6%$338.81 millionN/A0.00Gap Up
HOWL
Werewolf Therapeutics
0.3$11.60+11.3%$319.45 millionN/A0.00
Sensei Biotherapeutics logo
SNSE
Sensei Biotherapeutics
2.0$10.20+5.0%$312.00 millionN/A0.00Earnings Announcement
IMPL
Impel NeuroPharma
0.3$13.95+2.4%$270.84 millionN/A0.00
Kaleido Biosciences logo
KLDO
Kaleido Biosciences
1.5$5.82+9.3%$247.46 millionN/A-2.30
Unity Biotechnology logo
UBX
Unity Biotechnology
1.3$4.26+3.5%$233.40 millionN/A-2.27Earnings Announcement
VINC
Vincerx Pharma
1.0$16.34+1.0%$228.50 millionN/A0.00
RPHM
Reneo Pharmaceuticals
2.0$8.01+39.2%$193.93 millionN/A0.00Quiet Period Expiration
Annovis Bio logo
ANVS
Annovis Bio
1.7$23.28+7.3%$161.73 millionN/A0.00Upcoming Earnings
Analyst Report
News Coverage
Gap Up
Decibel Therapeutics logo
DBTX
Decibel Therapeutics
2.1$6.39+11.1%$159.12 millionN/A0.00Analyst Downgrade
News Coverage
LBPH
Longboard Pharmaceuticals
1.9$8.76+5.9%$148.19 millionN/A0.00
ImmunoPrecise Antibodies logo
IPA
ImmunoPrecise Antibodies
0.0$7.50+9.3%$143.77 millionN/A0.00Gap Up
GANX
Gain Therapeutics
1.7$9.00+8.7%$106.89 millionN/A0.00
EVAX
Evaxion Biotech A/S
1.7$5.30+5.7%$101.76 millionN/A0.00News Coverage
Gap Down
LGVN
Longeveron
0.0$5.20+1.9%$98.58 millionN/A0.00News Coverage
VRDN
Viridian Therapeutics
1.7$17.52+3.8%$68.47 millionN/A0.00
UPC
Universe Pharmaceuticals
0.0$3.09+4.5%$67.21 millionN/A0.00
Inhibikase Therapeutics logo
IKT
Inhibikase Therapeutics
1.0$4.90+9.0%$49.29 millionN/A0.00Gap Down
CUBT
Curative Biotechnology
0.0$0.11+8.7%$44.64 millionN/A0.00Gap Up
This page was last updated on 5/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.